AKT1 and cancer: These results were matched with clinical data which confirmed the action of Ola as a PARP inhibitor to induce death of the cancer cells.[22] The expression patterns of ERK and AKT factors in BRCA‐mut between the Ola and PTX/CBP treatment groups were aligned.